In particular, the overexpression of TFAP2A (Figure 1A) was mostly observed among cancers, including LUAD and LUSC (p < 0.01), whereas the downregulation of this gene was only observed in kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP) and prostate adenocarcinoma (PRAD). This evidence concerns the gene TFAP2A and prostate adenocarcinoma.